2歳から18歳未満の全身性重症筋無力症の小児におけるニポカリマブの試験

基本情報

NCT ID

NCT05265273

ステータス

募集中

試験のフェーズ

第2/第3相

試験タイプ

介入

目標被験者数

12

治験依頼者名

Janssen Research & Development, LLC

概要

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)